A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 471
- Registration Number
- NCT00974974
- Locations
- 🇺🇸
Investigator 7, Little Rock, Arkansas, United States
🇺🇸Investigator 64, Bradenton, Florida, United States
🇺🇸Investigator 4, Saint Petersburg, Florida, United States
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2019-11-06
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 23
- Registration Number
- NCT00914290
- Locations
- 🇺🇸
Northwest NeuroSpecialists, PLLC, Tucson, Arizona, United States
🇺🇸Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2009-04-14
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 381
- Registration Number
- NCT00880620
- Locations
- 🇺🇸
Coastal Neurological Medical Group, La Jolla, California, United States
🇺🇸Collaborative NeuroScience Network, Inc., Garden Grove, California, United States
🇺🇸Coordinated Clinical Research, La Jolla, California, United States
A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 27
- Registration Number
- NCT00869791
- Locations
- 🇺🇸
IMPAX Laboratories, Hayward, California, United States
Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 247
- Registration Number
- NCT00617695
IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2019-11-06
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 173
- Registration Number
- NCT00488839
- Locations
- 🇺🇸
Northwest NeuroSpecialists, Tucson, Arizona, United States
🇺🇸OrthoArkansas, P. A., Little Rock, Arkansas, United States
🇺🇸OrthoArkansas, P.A., Little Rock, Arkansas, United States
Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease
- First Posted Date
- 2006-01-20
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT00279825
- Locations
- 🇺🇸
Quest Research Institute, Bingham Farms, Michigan, United States
🇺🇸Oregon Health Sciences University - Parkinson's Center of Oregon, Portland, Oregon, United States
Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT00253084
- Locations
- 🇺🇸
Site 1, Chicago, Illinois, United States
🇺🇸Site 2, Charleston, South Carolina, United States
Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT00239564
- Locations
- 🇺🇸
Site 102, Lawrence, Kansas, United States
🇺🇸Site 101, Sunnyvale, California, United States